Clinical trial · Observational
The Significance of Postoperative Muscle Wasting in Pancreatic Cancer
National Cheng Kung University Hospital
NCT06093009CI-TRIAL-00070749completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the impact of preoperative sarcopenia and postoperative skeletal muscle wasting on the outcomes of patients with resectable pancreatic cancer who underwent pancreatectomy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pancreatectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Overall survival
- timeFrame
- 10 years
- description
- Overall survival was measured as the period between the date of resection and the date of the last follow-up or death.
- measure
- Disease-free survival
- timeFrame
- 10 years
- description
- Disease-free survival was defined as the duration from resection to cancer relapse (local, peritoneal recurrence, or distal metastasis).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 120 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of pancreatic cancer * Must be able to undergo pancreatectomy * Must be able to undergo pre- and post-operative abdominal computed tomography scan Exclusion Criteria: * Unresectable pancreatic cancer
References
Publications (0)
Data not yet available
No reference posted for this study.